Selecting the best|value biosimilar in emerging countries

Selecting the best-value biosimilar in emerging countries

The purpose of the present paper is to provide suggestions of criteria that can be useful for selecting the best-value biological in emerging countries.

Selecting the best-value biosimilar in emerging countries

The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries ...

Expert Consensus Recommendations on a Biosimilars Value ...

The expert panel agreed on a biosimilar value framework for the GCC countries that is founded on trust, cost savings and contextual considerations.

What's next for biosimilars in emerging markets? - McKinsey

Pushing for the inclusion of value criteria. Although tendering and contracting in developing ... have scope to shape the selection criteria. For instance ...

To date, there have been 41 approvals and 30 launches in the U.S. biosimilar market.biosimilar ... emerging market.

How to select a best-value biological medicine? A practical model to ...

With the growing availability of biosimilars on the global market, clinicians and pharmacists have multiple off-patent biological products to choose from.

Comparison of Uptake and Prices of Biosimilars in the US, Germany ...

An increasing number of biosimilars may spur competition and lower prices, as with generic drugs, and several countries have developed policies ...

We found that the medicines regulators take similar approaches to biosimilar approvals, but that differences in their policies and their jurisdiction's laws

Unlocking the Promising Opportunities of Biosimilars in the Middle ...

The biosimilar market is highly competitive and dynamic, wherein many players venture into the market creating substantial demand. According to ...

Emerging Insights into European Markets of Biologics, Including ...

In an analysis of the Bulgarian market for biologic disease-modifying antirheumatic medicines, Tachkov et al. showed that biosimilar market ...

... select the supplier that offers the best value. Twelve. European countries have single-winner tenders awarded to the manufacturer with the ...

At the time of launch, biosimilar products in emerging markets exhibit a manufacturer-level price representing an approximately 30% discount, on average, over ...

Winning with biosimilars Opportunities in global markets - Deloitte

Unlock access. After TA selection, the next step for biosimilars manufacturers is to consider how to drive adoption. Growth in emerging markets may be hampered ...

Observed trends in market shares indicate a biosimilar first-mover advantage whereas pricing strategies considered to be anti-competitive can ...

Geographically, the biosimilars market is segmented Europe, the Asia Pacific, North America, Latin America and Middle East and Africa. In 2022, ...

Best-value biological selection making: more to consider than only ...

With biosimilar medicines becoming available on the market, clinicians and pharmacists have multiple off-patent biological products to choose from. Moreover ...

The U.S. Generic & Biosimilar Medicines Savings Report

biosimilar company's ability to enter the market. During this time, patients often experience repeated price increases. ○ New generics and biosimilars generate ...

Policy recommendations on uptake of biosimilar medicines in the ...

If European countries had achieved a target biosimilar uptake level of 80% in 2020 ... ✓ In Ireland, the National Health Service put in place a 'Best Value' ...

What's next for biosimilars in emerging markets? - McKinsey

Projections suggest that global sales could more than double to $15 billion by the early 2020s, with an estimated $5 billion to $8 billion ...

Full article: A health economic guide to market access of biosimilars

Market access of biosimilars can contribute to this objective as a result of the lower price of biosimilars and price competition with alternative therapies.